SCHEMBL118050

SCHEMBL118050

C=CC(=O)NCCOc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
MTNR1A P48039 1/20 0.63
MTNR1B P49286 1/20 0.63
NPC1 O15118 5/20 0.61
HPGD P15428 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.57
THRB P10828 1/20 0.57
KMT2A Q03164 2/20 0.55
RECQL P46063 2/20 0.54
PKM P14618 2/20 0.52
EPHX2 P34913 1/20 0.52
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
CASP3 P42574 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
KDM4E B2RXH2 1/20 0.50
APOBEC3A P31941 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
TGM2 P21980 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10363148 0.90 TGM2 (0.58) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10363171 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10362509 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10362423 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10363983 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10362464 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10362422 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10362406 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10363121 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1
SCHEMBL10362434 0.89 TGM2 (0.60) RAB9ASMN1; SMN2MTNR1AMTNR1BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032398-A1 HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2025-01-30 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
EP-1964893-B2 Ink composition, inkjet recording method, printed material, and ink set FUJIFILM CORP (JP) 2021-11-24 EP disclosed
CN-108980623-B Kinetic inhibition oil-water emulsion responding to hydrate and preparation method and application thereof 东莞理工学院 2021-01-08 CN disclosed
US-20200062696-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-27 US disclosed
US-20200062696-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-27 US disclosed
US-20200054651-A1 COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-20 US disclosed
US-20200054651-A1 COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-20 US disclosed
CN-110785426-A Compositions and methods for modulating PPP2R1A 加利福尼亚大学董事会 2020-02-11 CN disclosed
US-20190382519-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2019-12-19 US disclosed
WO-2018132548-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2018-07-19 WO disclosed
EP-1964893-B1 Ink composition, inkjet recording method, printed material, and ink set FUJIFILM CORP (JP) 2018-01-24 EP disclosed
US-8733919-B2 Active energy ray-curable ink composition, inkjet recording method, and inkjet printed article FUJIFILM CORPORATION (JP) 2014-05-27 US disclosed
US-8733919-B2 Active energy ray-curable ink composition, inkjet recording method, and inkjet printed article FUJIFILM CORPORATION (JP) 2014-05-27 US disclosed
US-20120056930-A1 ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, INKJET RECORDING METHOD, AND INKJET PRINTED ARTICLE FUJIFILM CORPORATION (JP) 2012-03-08 US disclosed
US-20120056930-A1 ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, INKJET RECORDING METHOD, AND INKJET PRINTED ARTICLE FUJIFILM CORPORATION (JP) 2012-03-08 US disclosed
EP-1964893-A1 Ink composition, inkjet recording method, printed material, and ink set FUJIFILM Corporation (JP) 2008-09-03 EP disclosed
US-20080206527-A1 INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, AND INK SET FUJIFILM CORPORATION (JP) 2008-08-28 US disclosed
US-20080206527-A1 INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATERIAL, AND INK SET FUJIFILM CORPORATION (JP) 2008-08-28 US disclosed
US-20070042275-A1 Composition for optical recording, optical recording medium, and production method thereof FUJI PHOTO FILM CO., LTD. 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062696-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 RTN4, RTN3, RCN1 RAB9A 939/4885SMN1; SMN2 2138/4885MTNR1A 4352/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 RAB9A 2224/4885SMN1; SMN2 1834/4885MTNR1A 3953/4885
US-20190382519-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ADSL, ABHD6, APH1B RAB9A 4363/4885SMN1; SMN2 1394/4885MTNR1A 4792/4885
US-20250032398-A1 HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF PCNA, ADSL, APH1B RAB9A 4438/4885SMN1; SMN2 1567/4885MTNR1A 4636/4885
US-20200054651-A1 COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A PPP2R1A, PPP3CA, PPP2R2A RAB9A 716/4885SMN1; SMN2 2710/4885MTNR1A 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.